-transparent.png){kind=logo}
Eighteen patients with advanced gastric cancer were treated with cisplatin 80 mg/m2 d 1, doxorubicin 30 mg/m2 d 3 and mitomycin-C 12 mg/m2 d 3. One complete and 6 partial responses were observed in 17 evaluable patients (41%, confidence interval 17-65%). Median duration of response was 7 months; median survival was 8 months. One death due to toxicity was observed. This combination of 3 active drugs should not be recommended in cases of gastric cancers.
Related Publications
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
June 1990,
Tumori,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
May 1984,
European journal of cancer & clinical oncology,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
April 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
September 1984,
The British journal of surgery,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
January 1986,
Cancer chemotherapy and pharmacology,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
July 1985,
Gan to kagaku ryoho. Cancer & chemotherapy,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
January 1995,
Oncology,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
April 1978,
Cancer treatment reports,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
January 1986,
Anticancer research,
C Louvet, and
A de Gramont, and
B Demuynck, and
C Varette, and
B Lagadec, and
J Cady, and
M Krulik
August 1990,
Nihon Gan Chiryo Gakkai shi,
